drugset / Trial / NCT04839237

The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients

NCT04839237

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This studay evaluates the effect of liraglutide in the treatment of obese patients ande the influence of genetic factors on the curative effect.Half of participants will receive Liraglutide alone,while the other half who can not achieving adequate glycaemic control will receive Liraglutide and metformin in combination.

Timeline

Start
2017-12-01
Primary completion
2020-12-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous
Background Metformin Small molecule 0.5 g Oral

Indications